Looks like you’re on the UK site. Choose another location to see content specific to your location
Lilly and Boehringer Ingelheim report new linagliptin data
Lilly and Boehringer Ingelheim have reported clinical trial data demonstrating potential benefits of their diabetes drug linagliptin.
Results from randomised phase III clinical trials and a post-hoc analysis of the drug have been presented at the American Diabetes Association's latest scientific sessions, showcasing the safety and efficacy of the drug.
Data from one phase III trial showed that adding linagliptin to a background of basal insulin offered blood sugar level reductions, while the post-hoc analysis also generated encouraging results.
Dr Lance Sloan, president and chief medical officer at the Texas Institute for Kidney and Endocrine Disorders, said: "These new studies provide additional data further evaluating the efficacy and safety of linagliptin, alone or in combination, in adults with type 2 diabetes who have experienced insufficient glycaemic control on other treatments."
Linagliptin is approved for sale in the US under the trade name Tradjenta, for use in combination with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Last month, the manufacturers published data showing the drug's strong performance among African-American patients.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard